Use our free Weight Regain Prevention Planner
Whether you’re planning to stay on Wegovy long-term or thinking about coming off in the future, our free planner shows where your habits sit now and what to focus on.
It assesses the 8 habits that most strongly predict whether weight loss is maintained: diet quality, protein, meal planning, aerobic exercise, strength training, emotional eating, sleep, and stress.
The tool shows you which habits are already in place and which still need work, then generates a personalised plan. It takes around 3 minutes and is based on the same evidence and approach we use in our medication-supported programme.
If you select ‘staying on long-term’, the gap analysis still runs, so you can see where to focus while you’re on the medication.
Key milestones: what to expect on Wegovy
| Duration |
What typically happens |
Key considerations |
| 0 to 16 weeks |
Dose titration period from 0.25 mg to 2.4 mg |
Side effects most common; focus on tolerability and start building healthy habits |
| 16 to 68 weeks |
Average 14.9% weight loss; 86% achieve at least 5% |
Continue to build sustainable eating habits during this window |
| 68+ weeks |
Weight loss typically plateaus; focus shifts to maintenance |
Consider maintenance dose; review progress with clinician |
| 2 years (NHS limit) |
NICE-recommended maximum within specialist services |
Private prescriptions can continue if clinically appropriate |
| After stopping |
Around two-thirds of weight is typically regained within 1 year without support |
Habit formation during treatment is critical for maintenance |
Is Wegovy good for long-term use?
For most people, Wegovy is safe to use long-term, provided it remains well-tolerated, and your prescriber agrees it’s appropriate.
GLP-1 receptor agonists, as a drug class, have been in clinical use since 2005, and semaglutide has been licensed since 2017.
The STEP 1 trial showed average weight loss of 14.9% over 68 weeks, with around half of participants losing 15% or more of their body weight.1
The STEP 5 trial, which is the longest published study of semaglutide for weight management, followed people for 2 years.
Average weight loss was 15.2% at week 104, compared with 2.6% on placebo, and 77.1% achieved at least 5% weight loss.4
The most common side effects are gastrointestinal: nausea, vomiting, constipation, and diarrhoea. These are typically mild to moderate, most common during the 16-week titration period, and tend to settle as the body adjusts.
In STEP 1, 4.5% of participants stopped semaglutide due to gastrointestinal side effects.1
Long-term safety beyond 2 years is less well-established because trial follow-up periods haven’t extended further.
Real-world experience over the years since approval hasn’t surfaced major new safety signals at the licensed doses.
What’s new with Wegovy in 2026
The MHRA approved a higher dose of 7.2 mg weekly for Wegovy in early 2026, following the STEP UP trial results.5
Among adherent participants, average weight loss was 20.7% at 7.2 mg compared with 17.5% at 2.4 mg over 72 weeks.
In the broader analysis (which included participants with poor adherence), the figures were 18.7% at 7.2 mg and 15.6% at 2.4 mg.
Most people on Wegovy won’t need the 7.2 mg dose, but it’s an option to discuss with your prescriber if weight loss has stalled at 2.4 mg.
Since July 2024, Wegovy is also licensed by the MHRA to reduce the risk of serious cardiovascular events (heart attack, stroke) in adults with established cardiovascular disease and a body mass index (BMI) of 27 or above.6
When prescribed for cardiovascular disease, there’s no 2-year cap, because the goal isn’t weight loss alone.
How long will I continue to lose weight on Wegovy?
Weight loss on Wegovy typically continues for around 14 to 16 months before reaching a plateau. The STEP 1 trial showed that maximum weight loss was generally achieved by week 60 to 68.1
After 68 weeks on Wegovy 2.4 mg, the average weight loss is around 15%, though individual results vary. Some people lose 5 to 10%, while others reach 20% or more.
After reaching your plateau, the focus shifts from active weight loss to maintenance. This is when the habits you’ve built during treatment become particularly important.
Several factors influence how much weight you’ll lose:
- Starting weight and BMI
- How well you tolerate the medication
- Dietary changes made alongside treatment
- Physical activity levels
- Whether you have type 2 diabetes (weight loss tends to be lower)
The amount of weight you lose isn’t down to the medication alone. The eating patterns, activity levels, and stress and sleep habits you build while taking Wegovy all contribute.
Can I stay on a lower maintenance dose?
Yes, some people maintain their weight loss on a lower dose of Wegovy rather than the standard 2.4 mg. This approach can reduce side effects and lower medication costs.
Wegovy is available in five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, plus the new 7.2 mg dose for those who haven’t reached their target on 2.4 mg.
While 2.4 mg is the standard maintenance dose used in clinical trials, some people find that lower doses are sufficient once they’ve reached their weight-loss goals.
Clinical trials primarily studied the 2.4 mg dose, so there’s less data on long-term outcomes with lower maintenance doses.
Your prescriber can help you decide whether a lower maintenance dose might work for you based on:
- Your weight loss progress and current stability
- Side effect profile at different doses
- Your overall health goals
- Cost considerations
What does long-term Wegovy cost?
Cost is a real factor in how long you can realistically stay on Wegovy privately.
UK private prescription prices vary by provider and dose, but a year on a maintenance dose typically costs in the region of £1,800 to £3,000.
Two to three years of continuous use can add up to £3,500 to £9,000 or more.
This is worth weighing against the cost of weight regain. If stopping the medication leads to gradual regain, and that regain affects your health (blood pressure, blood sugar, joint pain, sleep apnoea), the comparison isn’t medication cost vs no cost: it’s medication cost vs the cost of treating regained weight and its consequences.
It’s also why building habits while on the medication is crucial. The stronger the habits you have in place, the lower the chance you’ll need to restart the medication later.
Reasons you might need to pause or stop Wegovy
Some decisions about how long to stay on Wegovy aren’t about weight loss progress. Three situations come up regularly:
Surgery or general anaesthesia
GLP-1 medications slow gastric emptying, which can increase the risk of food being retained in the stomach during anaesthesia.7
UK consensus guidance from the Association of Anaesthetists and the Royal College of Anaesthetists recommends pausing weekly GLP-1 medications, including Wegovy, for 1 week before elective surgery requiring sedation or general anaesthesia.7
Tell your surgical team that you’re on Wegovy well in advance of any planned procedure.
For emergency surgery, the anaesthetic team will manage the risk on the day of surgery. There’s no need to delay urgent care because of the medication.
Pregnancy planning or pregnancy
Wegovy isn’t recommended during pregnancy or while breastfeeding. The MHRA advises that women planning to conceive should stop Wegovy at least two months before trying, allowing time for the medication to clear the system.8
Unlike Mounjaro, Wegovy isn’t currently flagged by the MHRA as having a clinically significant interaction with oral contraceptives. Standard contraceptive precautions apply.
If you discover you’re pregnant while taking Wegovy, contact your prescriber promptly.
Persistent or significant side effects
If gastrointestinal side effects don’t settle after the titration period, or if you develop significant side effects at any point, your prescriber may suggest staying at a lower dose, pausing, or stopping entirely. This isn’t a failure of the medication: it’s a clinical decision based on benefit and tolerability.
What happens when you stop Wegovy
When you stop Wegovy, your appetite gradually returns to its previous levels as the medication clears your system, unless you’ve built habits that keep hunger in check.
Semaglutide has a half-life of around one week, so it takes approximately 5 to 7 weeks for the medication to fully clear your system.9
The STEP 1 trial extension specifically studied what happens after stopping semaglutide.
Participants regained an average of 11.6 percentage points of their lost weight within one year, representing about two-thirds of what they’d originally lost.3
This is why the habits you build while taking Wegovy are so important. If you’ve developed sustainable eating patterns, regular physical activity, and a healthier relationship with food, you’ll be in a stronger position to maintain lower hunger levels naturally.
There’s no published clinical guideline mandating tapering for Wegovy, because the medication doesn’t cause withdrawal.
The reason most prescribers recommend a gradual reduction is behavioural rather than pharmacological: stepping down gives you time to monitor how your appetite changes at each stage and to bed in the habits you’ll rely on once the medication is out of your system.
For the full tapering protocol and habit work that supports a smooth transition off the medication, see our dedicated guide on coming off GLP-1 medications. (The guide is written about Mounjaro, but the principles around tapering and post-medication habit-building apply to all GLP-1 receptor agonists, including Wegovy.)
NHS vs private prescription duration
There’s an important difference between NHS and private prescriptions when it comes to how long you can take Wegovy.
NHS prescriptions
NICE guidance (TA875) recommends that Wegovy be used for up to 2 years within a specialist weight management service.2
Treatment should be reviewed at 6 months, and NICE suggests considering stopping if less than 5% of the initial weight has been lost on the 2.4 mg dose.
The 2-year cap is a cost-effectiveness recommendation based on the duration of trial evidence available at the time of the appraisal. It’s not a safety threshold.
Many obesity specialists view obesity as a chronic condition requiring ongoing management, similar to high blood pressure or type 2 diabetes.
If you’re currently on an NHS prescription and approaching the 2-year limit, you have several options:
- Transition to a private prescription to continue treatment
- Gradually taper off with a plan for weight maintenance
- Discuss alternative medications or approaches with your specialist team
Private prescriptions
If you purchase Wegovy privately, there’s no fixed time limit. You can continue taking the medication for as long as:
- It remains medically appropriate
- You tolerate it well
- Your prescriber approves continued use
Frequently asked questions
Is Wegovy a lifelong medication?
Wegovy can be taken long-term, but it doesn’t have to be lifelong. Some people use it for 1 to 2 years to reach their goal weight while building sustainable habits, then taper off.
Others choose to continue indefinitely to maintain their weight. The right approach depends on your individual circumstances and should be discussed with your healthcare provider.
What happens when I reach my goal weight?
You have several options: continue at the same dose for maintenance, try a lower dose to maintain your weight, or gradually taper off while focusing on the habits you’ve developed.
Will I regain all the weight if I stop Wegovy?
Research shows that without ongoing intervention, people typically regain about two-thirds of their lost weight within a year of stopping.3
People who’ve developed sustainable eating and exercise habits during treatment tend to maintain better results, which is why behavioural support alongside medication matters so much.
How long does Wegovy stay in my system after stopping?
Semaglutide has a half-life of about one week. It takes approximately 5 to 7 weeks (around five half-lives) for the medication to be effectively cleared from your system after your final injection.9
Can I restart Wegovy if I regain weight after stopping?
Yes, in most cases you can restart Wegovy if you regain weight after stopping, provided you still meet the eligibility criteria, and your prescriber agrees it’s appropriate. You would typically restart at a lower dose and titrate back up.
Is the 2-year NHS limit based on safety concerns?
No. The 2-year limit exists because clinical trials hadn’t extensively studied outcomes beyond this duration when NICE made its recommendation, and because of cost-effectiveness modelling.
It’s not due to safety concerns with longer-term use. Private prescriptions can continue beyond 2 years if clinically appropriate.
Do I need to stop Wegovy before surgery?
For elective surgery requiring sedation or general anaesthesia, UK consensus guidance recommends pausing weekly GLP-1 medications, including Wegovy, for one week before the procedure.7 Tell your surgical team about your medication well in advance.
Can I take Wegovy if I’m planning to get pregnant?
No. The MHRA advises stopping Wegovy at least two months before trying to conceive.8 Wegovy isn’t recommended during pregnancy or breastfeeding.
What’s the difference between Wegovy and Ozempic?
Both contain semaglutide, but Wegovy is licensed for weight management at doses up to 2.4 mg a week (and 7.2 mg a week from 2026), while Ozempic is licensed for type 2 diabetes at doses up to 2 mg a week. Wegovy is the appropriate choice for weight management.
Should I take Wegovy or Mounjaro?
Both are effective weight-loss medications. Mounjaro (tirzepatide) works on both GLP-1 and GIP receptors and has shown greater average weight loss in trials (around 21% on the highest dose over 72 weeks compared with 15% for Wegovy 2.4 mg, or 21% on the new Wegovy 7.2 mg dose).
Your prescriber can help decide which is most suitable based on your medical history, preferences, and availability. For comparison, see our guide on how long you can stay on Mounjaro.
Take home message
You can stay on Wegovy as long as it’s helping you and you’re tolerating it well. There’s no fixed time limit for private prescriptions, though NHS prescriptions are currently limited to 2 years.
The STEP trials show that continuing Wegovy maintains weight loss, while stopping leads to a regain of around two-thirds of the weight lost within a year. The strength of your habits at the point of stopping is the biggest modifiable factor.
The eating patterns, activity habits, and coping strategies you build while on Wegovy shape what happens after. Surgery, pregnancy planning, side effects, and cost are all valid reasons to pause or stop, separate from weight loss progress.
If you haven’t already, scroll back up and use our Weight Regain Prevention Planner to see where your habits sit and what to focus on.
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
- National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity (TA875). Updated September 2023.
- Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.
- Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091.
- Wharton S, Freitas P, Hjelmesæth J, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949-963.
- Medicines and Healthcare products Regulatory Agency. (2024). MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults. Press release, 23 July 2024.
- El-Boghdadly K, et al. (2025). Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement. Anaesthesia.
- Medicines and Healthcare products Regulatory Agency. (2025). GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK, 5 June 2025.
- Electronic Medicines Compendium. (2024). Wegovy Summary of Product Characteristics. Novo Nordisk.
- Richards R, Lunt W, Whitman M, Spaltro G, Hall R. (2025). Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Formative Research, 9, e81912. doi:10.2196/81912.
